DNA alkylating agents are an important part of most dose-intensified chemotherapy protocols. In spite of increased use of myeloid growth factor and stem cell support, myelosuppression continues to be a dose-limiting toxicity of many alkylating agents. This is particularly true in patients with relapsed disease previously treated with intensive chemotherapy during induction and consolidation phases of initial therapies. One approach to circumvent the dose-limiting myeloid toxicities of chemotherapy agents has been the use of gene transfer to introduce and express genes important in chemotherapy resistance in bone marrow-derived cells. Work in our laboratory has concentrated on retroviral vectors encoding DNA repair proteins as a mechanism to generate resistance to chloroethylnitrosourea (CENUs) and other alkylating agents. In our previous studies, we have developed a murine model of CENU-induced fatal bone marrow suppression. Reconstitution of murine bone marrow with hematopoietic stem cells expressing vector-derived MGMT protects mice from BCNU-induced bone marrow hypoplasia and peripheral blood pancytopenia. Bone marrow cells harvested from these mice are more resistant to CENU in vitro, and demonstrate a higher level of DNA repair activity compared to CENU-treated mock-infected control mice. In the studies outlined here, we propose to continue our work on CENU-resistance by developing a new series of retroviral vectors which encode DNA repair activity resistant to depletion by the free base 06-benzylguanine, which would allow differential depletion of tumor versus bone marrow repair activity. In addition, we propose to expand this approach to include proteins of the base excision repair (BER) pathway, which are important in the repair of DNA damage from CENUs and other alkylating agents. Finally, we wish to develop vectors which would potentially prevent DNA damage from alkylating agents by increasing the expression of detoxifying proteins in bone marrow cells. Overall, this project seeks to use gene transfer technology to increase resistance of normal bone marrow to the cytotoxic effects of alkylating agent damage.
The specific aims i nclude: 1) Develop retroviral vectors which increase the therapeutic window of chloroethylnitrosourea (CENU)-based tumor killing in vivo utilizing 6-benzylguanine resistant methylguanine DNA methyltransferases expressed in bone marrow cells; 2) Examine the effect of transgene expression of components of the base excision repair (BER) pathway on CENU and alkylating (bleomycin, cyclophosphamide and thiotepa) agent resistance; and, 3) Examine the role of increased expression of aldehyde dehydrogenase and glutathione-S- transferase in resistance to cyclophosphamide. These basic studies are likely to lead to innovative clinical studies utilizing gene transfer technology in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA075426-04
Application #
6429987
Study Section
Project Start
2001-03-01
Project End
2002-02-28
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
2001
Total Cost
$220,099
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Hegde, Vijay; Wang, Mu; Deutsch, Walter A (2004) Human ribosomal protein S3 interacts with DNA base excision repair proteins hAPE/Ref-1 and hOGG1. Biochemistry 43:14211-7
Hegde, Vijay; Wang, Mu; Deutsch, Walter A (2004) Characterization of human ribosomal protein S3 binding to 7,8-dihydro-8-oxoguanine and abasic sites by surface plasmon resonance. DNA Repair (Amst) 3:121-6
Fishel, Melissa L; Seo, Young R; Smith, Martin L et al. (2003) Imbalancing the DNA base excision repair pathway in the mitochondria; targeting and overexpressing N-methylpurine DNA glycosylase in mitochondria leads to enhanced cell killing. Cancer Res 63:608-15
Kreklau, Emiko L; Pollok, Karen E; Bailey, Barbara J et al. (2003) Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea. Mol Cancer Ther 2:1321-9
Roth, Timothy J; Xu, Yi; Luo, Meihua et al. (2003) Human-yeast chimeric repair protein protects mammalian cells against alkylating agents: enhancement of MGMT protection. Cancer Gene Ther 10:603-10
Wu, M; Pasula, R; Smith, P A et al. (2003) Mapping alveolar binding sites in vivo using phage peptide libraries. Gene Ther 10:1429-36
Kelley, Mark R; Kow, Yoke W; Wilson 3rd, David M (2003) Disparity between DNA base excision repair in yeast and mammals: translational implications. Cancer Res 63:549-54
Dobson, Allison W; Grishko, Valentina; LeDoux, Susan P et al. (2002) Enhanced mtDNA repair capacity protects pulmonary artery endothelial cells from oxidant-mediated death. Am J Physiol Lung Cell Mol Physiol 283:L205-10
He, Ying-Hui; Xu, Yi; Kobune, Masayoshi et al. (2002) Escherichia coli FPG and human OGG1 reduce DNA damage and cytotoxicity by BCNU in human lung cells. Am J Physiol Lung Cell Mol Physiol 282:L50-5
Wu, Min; He, Ying-Hui; Kobune, Masayoshi et al. (2002) Protection of human lung cells against hyperoxia using the DNA base excision repair genes hOgg1 and Fpg. Am J Respir Crit Care Med 166:192-9

Showing the most recent 10 out of 34 publications